// App-Quantinova.ai

19016 : ALK2 and ALK3 BMP Type I Receptors Are Required for the Development of Cardiac Hypertrophy

Researchers

Presenter

  • Ester Spagnolli

Principal Investigators

  • Laura Ernande

  • Starsha Kolodziej

  • Claire Mayeur

  • Patricio Leyton

  • Marielle Scherrer-Crosbie

  • Kenneth D Bloch

Medical Centers

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Cardiovascular (CVS)

Disease

  • Hypertrophic cardiomyopathy

Biomarkers

  • Activin A receptor type II-like 1

  • Bone Morphogenetic Protein 7

  • Bone morphogenetic protein receptor, type IA

  • B-type natriuretic peptide

Drug/Treatment

  • Phenylephrine

  • Isoproterenol

  • noggin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved